TrialOncotarget2016

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Garrett S Barry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.